Fibrin clot structure in patients with congenital dysfibrinogenaemia

Thrombosis Research

Volumn 137, Issue , 2016, Pages 189-195

  Casini, A ^a,b   Duval, C ^b   Pan, X ^b   Tintillier, V ^c   Biron Andreani, C ^d   Ariens R A S ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HÔPITAL SAINT ELOI   (France)

Author keywords

Congenital dysfibrinogenaemia; Fibrinolysis; Laser scanner confocal microscopy; Mutation; Permeability

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN; FIBRINOGEN ALPHA; FIBRINOGEN CONCENTRATE; PROTHROMBIN; UNCLASSIFIED DRUG; FIBRIN; FIBRIN DEGRADATION PRODUCT;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; BLEEDING TENDENCY; COMPARATIVE STUDY; CONGENITAL BLOOD CLOTTING DISORDER; CONGENITAL DYSFIBRINOGENEMIA; CONTROLLED STUDY; DENSITY; DYSFIBRINOGENEMIA; EUGLOBULIN LYSIS TEST; EX VIVO STUDY; FEMALE; FIBRIN CLOT; FIBRIN POLYMERIZATION; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GENE MUTATION; GENOTYPE; HEMATOLOGICAL PARAMETERS; HUMAN; MEDICAL HISTORY; MENORRHAGIA; MISSENSE MUTATION; MOLECULAR SIZE; PERMEABILITY; PHENOTYPE; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; RECURRENT DISEASE; SKIN BLEEDING; TISSUE STRUCTURE; TURBIDITY; VEIN THROMBOSIS; AGED; BLOOD; CONGENITAL DYSERYTHROPOIETIC ANEMIA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; ULTRASTRUCTURE; YOUNG ADULT;

ADULT; AGED; ANEMIA, DYSERYTHROPOIETIC, CONGENITAL; FEMALE; FIBRIN; FIBRIN CLOT LYSIS TIME; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84952638008     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.11.008     Document Type: Article

References (42)

1. P. de Moerloose, A. Casini, and M. Neerman-Arbez Congenital fibrinogen disorders: an update Semin. Thromb. Hemost. 39 6 2013 585 595
2. R. Palla, F. Peyvandi, and A.D. Shapiro Rare bleeding disorders: diagnosis and treatment Blood 125 13 2015 2052 2061
3. A. Casini, M. Neerman-Arbez, R.A. Ariens, and et al. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management J. Thromb. Haemost. 13 6 2015 909 919
4. J.W. Weisel, and R.I. Litvinov Mechanisms of fibrin polymerization and clinical implications Blood 121 10 2013 1712 1719
5. A. Casini, M. Blondon, A. Lebreton, and et al. Natural history of patients with congenital dysfibrinogenemia Blood 125 3 2015 553 561
6. F. Haverkate, and M. Samama Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen Thromb. Haemost. 73 1 1995 151 161
7. A. Undas Fibrin clot properties and their modulation in thrombotic disorders Thromb. Haemost. 112 1 2014 32 42
8. K.I. Bridge, H. Philippou, and R. Ariens Clot properties and cardiovascular disease Thromb. Haemost. 112 5 2014 901 908
9. R.A. Ariens Fibrin(ogen) and thrombotic disease J. Thromb. Haemost. 11 Suppl. 1 2013 294 305
10. M. Zucker, U. Seligsohn, O. Salomon, and et al. Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency J. Thromb. Haemost. 12 7 2014 1121 1130
11. J. Soria, C. Soria, and P. Caen A new type of congenital dysfibrinogenaemia with defective fibrin lysis - Dusard syndrome: possible relation to thrombosis Br. J. Haematol. 53 4 1983 575 586
12. A. Undas, M. Pastuszczak, T. Iwaniec, and et al. Functional characterisation of plasma fibrin clots in Polish carriers of fibrinogen gammaArg275His mutation (fibrinogen Zabrze) Thromb. Haemost. 104 2 2010 415 417
13. R. Kotlin, O. Pastva, J. Stikarova, and et al. Two novel mutations in the fibrinogen gamma nodule Thromb. Res. 134 4 2014 901 908
14. R.C. Marchi, M.H. Meyer, N.B. de Bosch, and et al. A novel mutation (deletion of Aalpha-Asn 80) in an abnormal fibrinogen: fibrinogen Caracas VI. Consequences of disruption of the coiled coil for the polymerization of fibrin: peculiar clot structure and diminished stiffness of the clot Blood Coagul. Fibrinolysis 15 7 2004 559 567
15. T. Sugo, H. Endo, M. Matsuda, and et al. A classification of the fibrin network structures formed from the hereditary dysfibrinogens J. Thromb. Haemost. 4 8 2006 1738 1746
16. I.J. Mackie, S. Kitchen, S.J. Machin, and et al. Guidelines on fibrinogen assays Br. J. Haematol. 121 3 2003 396 404
17. F. Rodeghiero, A. Tosetto, T. Abshire, and et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders J. Thromb. Haemost. 8 9 2010 2063 2065
18. R.A. Ariens, H. Philippou, C. Nagaswami, and et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure Blood 96 3 2000 988 995
19. A.M. Carter, C.M. Cymbalista, T.D. Spector, and et al. Heritability of clot formation, morphology, and lysis: the EuroCLOT study Arterioscler. Thromb. Vasc. Biol. 27 12 2007 2783 2789
20. M. Pieters, A. Undas, R. Marchi, and et al. An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values J. Thromb. Haemost. 10 10 2012 2179 2181
21. C. Duval, P. Allan, S.D. Connell, and et al. Roles of fibrin alpha- and gamma-chain specific cross-linking by FXIIIa in fibrin structure and function Thromb. Haemost. 111 5 2014 842 850
22. D.J. Scott, P. Prasad, H. Philippou, and et al. Clot architecture is altered in abdominal aortic aneurysms and correlates with aneurysm size Arterioscler. Thromb. Vasc. Biol. 31 12 2011 3004 3010
23. M.T. Cunningham, J.T. Brandt, M. Laposata, and et al. Laboratory diagnosis of dysfibrinogenemia Arch. Pathol. Lab. Med. 126 4 2002 499 505
24. A.D. Mumford, S. Ackroyd, R. Alikhan, and et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology Br. J. Haematol. 167 3 2014 304 326
25. Q. Bin, F. Liang, D.Y. Ou, and et al. Two symptomatic cases of dysfibrinogenemia in China: one with gamma-chain Arg275Cys mutation and another without detectable mutation in fibrinogen genes Blood Coagul. Fibrinolysis 26 5 2015 564 571
26. P. Reber, M. Furlan, A. Henschen, and et al. Three abnormal fibrinogen variants with the same amino acid substitution (gamma 275 Arg - - His): fibrinogens Bergamo II, Essen and Perugia Thromb. Haemost. 56 3 1986 401 406
27. S.E. Shapiro, E. Phillips, R.A. Manning, and et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia Br. J. Haematol. 160 2 2013 220 227
28. R. Kotlin, Z. Reicheltova, M. Maly, and et al. Two cases of congenital dysfibrinogenemia associated with thrombosis - Fibrinogen Praha III and Fibrinogen Plzen Thromb. Haemost. 102 3 2009 479 486
29. R. Kotlin, M. Chytilova, J. Suttnar, and et al. Fibrinogen Novy Jicin and Praha II: cases of hereditary Aalpha 16 Arg → Cys and Aalpha 16 Arg → His dysfibrinogenemia Thromb. Res. 121 1 2007 75 84
30. M. Meyer, G. Kutscher, J. Sturzebecher, and et al. Fibrinogen Magdeburg I: a novel variant of human fibrinogen with an amino acid exchange in the fibrinopeptide A (Aalpha 9, Leu → Pro) Thromb. Res. 109 2-3 2003 145 151
31. T. Lisman, P.G. de Groot, J.C. Meijers, and et al. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis Blood 105 3 2005 1102 1105
32. K. Bakhtiari, P.W. Kamphuisen, M.E. Mancuso, and et al. Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients Br. J. Haematol. 162 6 2013 827 835
33. L. Traby, M. Kollars, L. Eischer, and et al. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study PLoS One 7 12 2012 e51447
34. M. Konieczynska, K. Fil, M. Bazanek, and et al. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis Thromb. Haemost. 111 4 2014 685 693
35. A. Undas, L. Zubkiewicz-Usnarska, G. Helbig, and et al. Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma Eur. J. Clin. Investig. 44 6 2014 557 566
36. S.K. Westbury, C. Duval, H. Philippou, and et al. Partial deletion of the alphaC-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis Thromb. Haemost. 110 6 2013 1135 1144
37. J.P. Collet, J.L. Woodhead, J. Soria, and et al. Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots Biophys. J. 70 1 1996 500 510
38. M.W. Mosesson, K.R. Siebenlist, J. Hainfeld, and et al. The relationship between the fibrinogen D domain self-association/cross-linking site (gammaXL) and the fibrinogen Dusart abnormality (Aalpha R554C-albumin): clues to thrombophilia in the "Dusart syndrome" J. Clin. Invest. 97 10 1996 2342 2350
39. B.C. Lim, R.A. Ariens, A.M. Carter, and et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk Lancet 361 9367 2003 1424 1431
40. T. Sugo, C. Nakamikawa, N. Yoshida, and et al. End-linked homodimers in fibrinogen Osaka VI with a B beta-chain extension lead to fragile clot structure Blood 96 12 2000 3779 3785
41. D. Pietrys, W. Balwierz, T. Iwaniec, and et al. Two different fibrinogen gene mutations associated with bleeding in the same family (A alphaGly13Glu and gammaGly16Ser) and their impact on fibrin clot properties: fibrinogen Krakow II and Krakow III Thromb. Haemost. 106 3 2011 558 560
42. A. Undas, and R.A. Ariens Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases Arterioscler. Thromb. Vasc. Biol. 31 12 2011 e88 e99